Skip to main content
Start triage

Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Need urgent help? Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Roxee Meds Catalog

Desoxycorticosterone Pivalate

Medication catalog facts with explicit FDA-approval, off-label, source-limited, and safety context.

Both Catalog complete FDA data linked Rx required Liquid (Suspension) Multiple FDA labelers Official label facts Owner quick guide first
Start Symptom Intake Talk to a Vet / Find a Vet Near You

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Storefront facts
Catalog refreshed
May 5, 2026, 10:00 a.m.

These are the storefront facts Roxee uses on browse cards and quick facts.

FDA applications
FDA application data refreshed
May 5, 2026, 10:00 a.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports
Safety data refreshed
Apr 26, 2026, 10:02 a.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details
Source timing details
  • Storefront facts: Source Roxee | Refreshed May 5, 2026, 10:00 AM UTC
    The storefront fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC

Evidence

Reviewed / Updated / Sources

Reviewed by: Not available

Last reviewed: February 12, 2026

Updated: February 12, 2026, 10:44 PM UTC

Sources:
Image coming soon
Desoxycorticosterone Pivalate

Desoxycorticosterone Pivalate

Drug type: Generic ingredient • Branded profile • FDA branded products available

Both Liquid (Suspension) Rx required 100% storefront ready

Species: Both

Manufacturer: Multiple FDA labelers

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Desoxycorticosterone Pivalate

For use as replacement therapy for the mineralocorticoid deficit in dogs with primary adrenocortical insufficiency. For use as replacement therapy for mineralocorticoid deficiency in dogs with primary hypoadrenocorticism (Addison’s disease). Species commonly shown: Both, Dog, Restricted During Pregnancy, Dog, No Use Class Stated Or Implied.

Generic name
Desoxycorticosterone Pivalate
Brand names
Percorten™-V, Zycortal® Suspension, ZYCORTAL, Desoxycorticosterone Pivalate
Manufacturer
Multiple FDA labelers
Species
Both, Dog, Restricted During Pregnancy, Dog, No Use Class Stated Or Implied
Dosage forms
Liquid (Suspension), Injectable Suspension
Prescription
Prescription required
Completeness
100%
Validation
Complete
Brand names
Percorten™-V Zycortal® Suspension ZYCORTAL Desoxycorticosterone Pivalate
Dosage forms
Liquid (Suspension) Injectable Suspension

Indications / Uses

For use as replacement therapy for the mineralocorticoid deficit in dogs with primary adrenocortical insufficiency. For use as replacement therapy for mineralocorticoid deficiency in dogs with primary hypoadrenocorticism (Addison’s disease).

Warnings / Contraindications

For intramuscular use only. Do not use in pregnant dogs, dogs suffering from congestive heart disease, severe renal disease, or edema. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

  • For intramuscular use only. Do not use in pregnant dogs, dogs suffering from congestive heart disease, severe renal disease, or edema. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Side Effects

Top reported reactions (openFDA): Immediate pain upon injection, High sodium-potassium ratio (Na:K ratio), Lethargy (see also Central nervous system depression in 'Neurological'), Vomiting, Polyuria, Polydipsia.

FAQ

Both, Dog, Restricted During Pregnancy, Dog, No Use Class Stated Or Implied

Yes. Roxee shows this as prescription-only.

Liquid (Suspension), Injectable Suspension

Related Conditions

Addison’s Disease (Hypoadrenocorticism) Hypoadrenocorticism (Addison’s)

Source Transparency

Add to My Pet's Meds

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

For use as replacement therapy for the mineralocorticoid deficit in dogs with primary adrenocortical insufficiency.

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

  • For intramuscular use only
  • Do not use in pregnant dogs, dogs suffering from congestive heart disease, severe renal disease, or edema
  • For subcutaneous use in dogs only
  • wobbly/unsteady walking (1 reports)
  • Lymphopenia (1 reports)
  • Loss of appetite (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

Regulatory restrictions are shown in Vet View.

What to tell or ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?
Major cautions & emergency warning signs

Side effects to monitor:

  • For intramuscular use only
  • Do not use in pregnant dogs, dogs suffering from congestive heart disease, severe renal disease, or edema
  • For subcutaneous use in dogs only
  • wobbly/unsteady walking
  • Lymphopenia

Most reported reactions:

  • Unsteady walking (ataxia) (1 reports)
  • Lymphopenia (1 reports)
  • Loss of appetite (1 reports)

Emergency warning signs:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: Multiple FDA labelers
Form: Injectable Suspension, Liquid (Suspension)
Identifiers:
NADA: 141029 NADA: 141444 NDC Package: 17033-382-04 NDC Package: 58198-6450-0 NDC Product: 17033 NDC Product: 58198
Source metadata:

Warnings / Contraindications

For intramuscular use only. Do not use in pregnant dogs, dogs suffering from congestive heart disease, severe renal disease, or edema. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

  • High: For intramuscular use only. Do not use in pregnant dogs, dogs suffering from congestive heart disease, severe renal disease, or edema. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
27
Species represented
2
Grouped by Body System
Digestive (2) · Loss of appetite, Decreased appetite Skin & allergy (1) · Itching Neurologic (1) · Unsteady walking (ataxia) Effectiveness (2) · Lack of efficacy - NOS, Lack of efficacy (endoparasite) - whipworm Other (26) · Lymphopenia, Localised oedema, Leucocytosis NOS
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Neurologic 1 Dog 1
Other 1 Cat 1
Digestive 1 Cat 1
Other 1 Dog 1
Other 1 Dog 1
Effectiveness 1 Dog 1
Other 1 Dog 1
Other 1 Cat 1

Species coverage: Cat (17) Dog (15)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Neurologic Dog Serious - 1
Other Cat Serious - 1
Digestive Cat Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Effectiveness Cat Non-serious - 1
Effectiveness Dog Serious - 1
Other Dog Serious - 1
Skin & allergy Dog Non-serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Cat Non-serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Non-serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Digestive Cat Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Source metadata:

Documents

Owner handouts and official technical documents open on-page first, with the original source still one click away.

Owner handouts

0
No owner handouts linked yet.

Official label / PI

0
No official label or package insert links yet.

SPL

4

FOI

2

Percorten™-V

SPL · SPL

Open original
FDA Structured Product Label

Percorten™-V

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Elanco US Inc.
NADA
141-029
Status
RX
Form
Liquid (Suspension)
Route
Intramuscular
Species
Dog, Restricted During Pregnancy
Composition / specifications
Each milliliter of sterile aqueous suspension contains 25 milligrams of desoxycorticosterone pivalate.

Dogs

Indication
For use as replacement therapy for the mineralocorticoid deficit in dogs with primary adrenocortical insufficiency.
Dosage
Dosage requirements are variable and must be individualized on the basis of the response of the patient to therapy. Initial dose of 1 milligram per pound (0.45 kilogram) of body weight every 25 days, intramuscularly. Usual dose is 0.75 to 1.0 milligram per pound of body weight every 21 to 30 days.
Limitations
For intramuscular use only. Do not use in pregnant dogs, dogs suffering from congestive heart disease, severe renal disease, or edema. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Zycortal® Suspension

SPL · SPL

Open original
FDA Structured Product Label

Zycortal® Suspension

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Dechra, Ltd.
NADA
141-444
Status
RX
Form
Injectable Suspension
Route
Subcutaneous
Species
Dog, No Use Class Stated Or Implied
Composition / specifications
25 mg/mL

Dogs

Indication
For use as replacement therapy for mineralocorticoid deficiency in dogs with primary hypoadrenocorticism (Addison’s disease).
Dosage
Administer an initial dose of 2.2 mg/kilogram (1 mg/lb) body weight by subcutaneous injection. Subsequent dosages should be individualized according to label instructions based on patient response to therapy.
Limitations
For subcutaneous use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Desoxycorticosterone Pivalate SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for Desoxycorticosterone Pivalate. Use the source link for the full official labeling record.

ZYCORTAL SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for ZYCORTAL. Use the source link for the full official labeling record.

N141029 Org_1_12_1998.pdf

FOI · FOI

Open original

UCM488818.pdf

FOI · FOI

Open original
Source metadata:
Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Storefront facts: Source Roxee | Refreshed May 5, 2026, 10:00 AM UTC
    The storefront fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
Official (FDA)
Identity: Generic ingredient • FDA branded products available
Official FDA brands: Desoxycorticosterone Pivalate ZYCORTAL
Manufacturer mapping: Multiple FDA labelers
Case-reported brands (openFDA): MSK
Catalog species: Both • FDA-labeled species: Dog
Rx/OTC: RX
Form/route: Injectable Suspension, Liquid (Suspension) • Intramuscular, Subcutaneous
Applications: NADA 141-029 • NADA 141-444
NDC: Packages 17033-382-04 58198-6450-0 • Products 17033 58198
Documents: 2 (FOI: 2) • SPL: 2 • Label highlights • Official documents
Safety (openFDA)
Top reactions: Dog 12 • Cat 0 • View
Case summaries: 2 (showing 2) • View
openFDA reports are unverified and do not prove causation.
Explore
Linked using: Fda_Label (0.95), Fda_Label (0.95)
Diagnosis Codes
ICD10_CM: E27.1
Primary adrenocortical insufficiency

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • For intramuscular use only. Do not use in pregnant dogs, dogs suffering from congestive heart disease, severe renal disease, or edema. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian. (Contraindication, High)
Top reaction signals
Unsteady walking (ataxia) (1) Lymphopenia (1) Loss of appetite (1) Localised oedema (1) Leucocytosis NOS (1) Lack of efficacy (endoparasite) - whipworm (1) Laboured breathing (1) Increased red blood cell count (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
NADA: 141029 NADA: 141444 NDC Package: 17033-382-04 NDC Package: 58198-6450-0 NDC Product: 17033 NDC Product: 58198
Package NDC Product NDC Form / Route Status
17033-382-04 17033 -
58198-6450-0 58198 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

  • Desoxycorticosterone Pivalate SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • ZYCORTAL SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • N141029 Org_1_12_1998.pdf • FOI summary • Official • June 18, 2018
    FDA FOI summary for application 141029
  • UCM488818.pdf • FOI summary • Official • June 1, 2016
    FDA FOI summary for application 141444

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 30 Clinical 1 Manufacturer 0 Marketing 0
Current Field Facts
  • side_effects: Top reported reactions (openFDA): Immediate pain upon injection, High sodium-potassium ratio (Na:K ratio), Lethargy (see also Central nervous system depression… (Clinical, 2026-04-11)
  • contraindications: For intramuscular use only. Do not use in pregnant dogs, dogs suffering from congestive heart disease, severe renal disease, or edema. Federal law restricts th… (Official, 2026-04-12)
  • contraindications: For intramuscular use only. Do not use in pregnant dogs, dogs suffering from congestive heart disease, severe renal disease, or edema. Federal law restricts th… (Official, 2026-04-11)
  • contraindications: For intramuscular use only. Do not use in pregnant dogs, dogs suffering from congestive heart disease, severe renal disease, or edema. Federal law restricts th… (Official, 2026-02-12)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-05-05)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-05-03)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-05-02)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-04-29)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-04-28)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-04-27)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-04-26)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-04-25)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-04-22)
  • prescription_required: Rx required (Official, 2026-05-05)
  • prescription_required: Rx required (Official, 2026-05-03)
  • prescription_required: Rx required (Official, 2026-05-02)
  • prescription_required: Rx required (Official, 2026-04-29)
  • prescription_required: Rx required (Official, 2026-04-28)
  • prescription_required: Rx required (Official, 2026-04-27)
  • prescription_required: Rx required (Official, 2026-04-26)
Recent Revisions
  • side_effects updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
Percorten™-V
RX
Desoxycorticosterone Pivalate
Liquid (Suspension) • Intramuscular
Label highlights
Official documents
Elanco US Inc. NADA 141-029 Approved Jun 18, 2018
Zycortal® Suspension
RX
Desoxycorticosterone Pivalate
Injectable Suspension • Subcutaneous
Label highlights
Official documents
Dechra, Ltd. NADA 141-444 Approved Jun 1, 2016

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Dog, Restricted During Pregnancy
Composition / specifications
Each milliliter of sterile aqueous suspension contains 25 milligrams of desoxycorticosterone pivalate.
Dogs
Indication
For use as replacement therapy for the mineralocorticoid deficit in dogs with primary adrenocortical insufficiency.
Dosage
Dosage requirements are variable and must be individualized on the basis of the response of the patient to therapy. Initial dose of 1 milligram per pound (0.45 kilogram) of body weight every 25 days, intramuscularly. Usual dose is 0.75 to 1.0 milligram per pound of body weight every 21 to 30 days.
Limitations
For intramuscular use only. Do not use in pregnant dogs, dogs suffering from congestive heart disease, severe renal disease, or edema. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
25 mg/mL
Dogs
Indication
For use as replacement therapy for mineralocorticoid deficiency in dogs with primary hypoadrenocorticism (Addison’s disease).
Dosage
Administer an initial dose of 2.2 mg/kilogram (1 mg/lb) body weight by subcutaneous injection. Subsequent dosages should be individualized according to label instructions based on patient response to therapy.
Limitations
For subcutaneous use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Usage

For use as replacement therapy for the mineralocorticoid deficit in dogs with primary adrenocortical insufficiency. For use as replacement therapy for mineralocorticoid deficiency in dogs with primary hypoadrenocorticism (Addison’s disease).

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

For intramuscular use only. Do not use in pregnant dogs, dogs suffering from congestive heart disease, severe renal disease, or edema. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive
Loss of appetite (1) • Cat Decreased appetite (1) • Cat

Showing top 5 for Digestive.

Skin & allergy
Itching (1) • Dog

Showing top 5 for Skin & allergy.

Neurologic
Unsteady walking (1) • Dog

Showing top 5 for Neurologic.

Effectiveness
Lack of efficacy - NOS (1) • Cat Lack of efficacy (endoparasite) - whipworm (1) • Dog

Showing top 5 for Effectiveness.

Other
Lymphopenia (1) • Cat Localised oedema (1) • Dog Leucocytosis NOS (1) • Dog Laboured breathing (1) • Dog Increased red blood cell count (1) • Cat
Show more (21)
Increased packed cell volume (1) • Cat Hyposensitivity to pain (1) • Dog Hyponatremia (1) • Cat Hypoglycaemia (1) • Cat Hypochloraemia (1) • Dog Hyperkalaemia (1) • Cat Hyperglycaemia (1) • Cat Hyperalbuminaemia (1) • Cat Hyperactivity (1) • Dog High sodium-potassium ratio (1) • Dog Gastrointestinal foreign body NOS (1) • Cat Fever (1) • Dog Falling (1) • Cat Dry mucous membrane (1) • Dog Drunken gait (1) • Dog Drug administration error (1) • Cat Disorientation (1) • Cat Dehydration (1) • Cat Coprophagia (1) • Dog Addison's disease (1) • Dog Abnormal ultrasound finding (1) • Cat

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Shepherd Dog - Australian, Male, 15 year, 6.804 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Unsteady walking (ataxia), Unable to walk, Pale mucous membrane, Dry mucous membrane, Laboured breathing… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-064279
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 15.00 Year
  • Weight: 6.804 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Unsteady walking (ataxia) Unable to walk Pale mucous membrane Dry mucous membrane Laboured breathing Pericardial effusion Leucocytosis NOS
Outcomes: Ongoing

Dog, ['Chihuahua', 'Dog (unknown)'], Female, 13 year, 10.45 kilogram • Drug: MSK, Unknown • Reactions: Weight gain, Polyuria, Polydipsia, High sodium-potassium ratio, Localised oedema • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-065692
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 13.00 Year
  • Weight: 10.450 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Weight gain Polyuria Polydipsia High sodium-potassium ratio Localised oedema
Outcomes: Outcome Unknown

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.